A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice.

ABSTRACT:

Background and aims

A prophylactic vaccine targeting multiple HCV genotypes (gt) is urgently required to meet World Health Organization elimination targets. Neutralizing antibodies (nAbs) and CD4⁺ and CD8⁺ T cells are associated with spontaneous clearance of HCV, and each may contribute to protective immunity. However, current vaccine candidates generate either nAbs or T cells targeting genetically variable epitopes and have failed to show efficacy in human trials. We have previously shown that a simian adenovirus vector (ChAdOx1) encoding conserved sequences across gt1-6 (ChAd-Gt1-6), and separately gt-1a E2 protein with variable regions deleted (E2Δ123_HMW ), generates pan-genotypic T cells and nAbs, respectively. We now aim to develop a vaccine to

SUBMITTER: Donnison T 

PROVIDER: S-EPMC9790311 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature